Shares in Sequenom sank by double digits for the second week in a row to lead all decliners in the BCW Index for the week ended Tuesday. Sequenom dropped 12.08 percent for the week, following a drop of 13.24 percent the week before. Though the firm has not revealed any bad news recently, Lehman Brothers dumped 1 million shares of Sequenom stock last week at a price of $4.55 per share.
 
Beckman Coulter led all gainers for the week with a 6.62 percent rise, followed by Illumina, which closed up 5.67 percent.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The UK's Nuffield Council on Bioethics says genetically modifying human embryos could be morally permissible, according to the Guardian.

A new Nature Biotechnology paper reports that CRISPR-Cas9 gene editing can lead to large deletions or complex rearrangements that could be pathogenic.

The Wall Street Journal likens a prototype developed by Synthetic Genomics to a "biological fax machine."

In PNAS this week: strategy for reactivating Rett syndrome-linked MECP2, small molecules able to suppress Staphylococcus aureus virulence, and more.